Drug Trial Radar · NCT07054099
A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years
Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
474
Planned (sponsor's estimate)
Start
Mar 17, 2026
Primary completion
Aug 2027
Study completion Jul 2036
Sponsor
- Lead sponsor
- GC Biopharma CorpIndustry
- Sponsor type
- Industry
- First posted
- Jul 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 months, up to 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical study aims to evaluate the safety and immune response of MG1111, in healthy children compared to VARIVAX. The study will follow participants for 42 days after receiving two doses, with additional follow-ups for up to 10 years to monitor varicella infection.
Conditions
- Varicella (Chickenpox)
- Chickenpox Vaccine
Interventions
MG1111 (Barycela inj.)Biological
MG1111 (Barycela inj.)
VARIVAX™Biological
Varivax™
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants who achieved seroconversion at 42 days after second vaccinationTime frame: 42 days after second vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Srinagarind Hospital
Khon Kaen, Changwat Khon Kaen, Thailand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.